Clinical trial
Open access
Jul 2026
Academic anti CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study
The anti-CD19 CAR T-cell product demonstrates good efficacy and acceptable toxicity in patients with r/r BCL and is the only available option for patients in countries where commercial products are not accessible.
N. Konoplya, T. Doroshenko, Katsiaryna Yu. Zharkova et al.
· Frontiers in Oncology · 0 citations